Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first-in-human

- PMLiVE

GSK’s Omjjara approved by EC to treat myelofibrosis patients with anaemia

About 40% of myelofibrosis patients have moderate-to-severe anaemia at the time of diagnosis

Imagery icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why imagery matters…

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Cuttsy + Cuttsy

Health literacy icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why health literacy matters…

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Cuttsy + Cuttsy

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

EU flag

EC opens participation to new alliance addressing critical drug shortages

The Critical Medicines Alliance is expected to publish its first advice by autumn 2024

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

EU flag

EC approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Impetus Digital

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links